Burning Rock Biotech Limited (NASDAQ: BNR) announced that all shareholder resolutions proposed at the 2025 annual general meeting were passed. Resolutions included the ratification of Ernst & Young Hua Ming LLP as auditor and re-election of directors Feng Deng and Licen Lisa Xu. Burning Rock focuses on NGS technology in precision oncology, offering therapy selection testing for late-stage cancer patients and cancer early detection. The company’s mission is to guard life via science, with a business that has moved beyond R&D into clinical validation. For more information, visit ir.brbiotech.com. Contact [email protected] for inquiries.

Read more at GlobeNewswire: Burning Rock Announces Results of 2025 Annual General